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Commercial vaccines against human papillomavirus (HPV) have low uptake due to parental autonomy,
dosing regimen, cost, and cold chain storage requirements. Carrageenan (CG)-based formulations prevent
HPV infection in vitro and in vivo but data are needed on the durability of anti-HPV activity and the effect
of seminal plasma (SP).
The Population Council’s PC-515 gel and the lubricant Divine 9 were tested for their physicochemical
properties and anti-HPV activity against HPV16, 18, and 45 pseudoviruses (PsVs). Anti-PsV activity was
estimated using the luciferase assay in HeLa cells and the HPV PsV luciferase mouse model. Formulations
were applied intravaginally either 2 h pre/2 h post (2 h/+2 h) or 24 h pre (24 h) relative to challenge
with HPV16 or 45 PsV in PBS or SP/PBS.
Both formulations showed broad-spectrum anti-HPV activity in vitro (IC50: 1–20 ng/ml), signiﬁcantly
decreasing HPV PsV infection in the mouse model (2 h/+2 h, p < 0.0001). PC-515 protected better than
Divine 9 in the 24 h dosing regimen (p < 0.0001) and comparable to Divine 9 in the 2 h/+2 h regimen
(p = 0.9841). PC-515 retained full activity in the murine model when PsV solutions contained human SP.
The durable, potential broad-spectrum anti-HPV activity of CG formulations in the presence of SP sup-
ports their further development to prevent HPV acquisition.
 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
HPV is the most common sexually transmitted infection (STI).
Forty different HPV types infect the anogenital mucosa; 15 have
been associated with carcinogenesis. HPV-16 and 18 account for
most of the invasive cervical and anal cancers, although co-infec-
tion with other carcinogenic genotypes occurs (Armstrong, 2010;
Massad et al., 2009; Schiller et al., 2012).
Gardasil, a quadrivalent vaccine (types 6, 11, 16 and 18), and
Cervarix, a bivalent vaccine (types 16 and 18), prevent new HPV
infections (Schiller et al., 2012). Both are listed as subsidized vac-
cines in underserved and poor countries by Global Alliance for Vac-
cines and Immunization. The beneﬁts of a global HPV vaccination
program are undeniable. But the vaccines do not protect against36 other HPV types associated with anogenital infections and have
low uptake due, in part, to high cost and cold chain storage
requirements (Lowy and Schiller, 2012).
Results from the CAPRISA-004 trial of vaginally administered
tenofovir gel (Abdool Karim et al., 2010) and oral pre-exposure
prophylaxis (PrEP) trials (Celum and Baeten, 2012) showed that
oral or topical PrEP can prevent STI acquisition. Carrageenan
(CG), a seaweed-derived polysaccharide, potently inhibits HPV
infection in vitro (at neutral and acidic pH) and in vivo (Buck
et al., 2006; Roberts et al., 2007). Additionally, analysis of data from
highly adherent participants in the Carraguard (PC-515, 3% CG)
Phase 3 trial suggested that CG decreases HPV acquisition
(Marais et al., 2011). These data, combined with the excellent
safety proﬁle of CG (Crostarosa et al., 2009; Kilmarx et al., 2008,
2006; Martin et al., 2010; Skoler-Karpoff et al., 2008; Turville
et al., 2008; Whitehead et al., 2006), have supported clinical testing
of PC-515 and Divine 9 gel to prevent HPV. Here we compare the
physicochemical properties of both gels, examining their in vitro
and in vivo efﬁcacy against different HPV types. Additionally we
evaluate the effect of SP on the in vivo anti-HPV activity of PC-515.
Table 1
Formulation attributes.
Property PC-515 Divine 9
Carrageenan content (mg/ml) 30.6 14.0
pH 7.0 7.0
Osmolality (mOsmol/kg) 326 <100
Viscosity (cP @ 37 C, 5 rpm) 33,000 1600
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2.1. Gel preparation
High lambda CG (Gelymar, Puerto Montt, Chile) was dissolved
at 3% (w/v) in phosphate buffered saline (PBS) at 70 C, 3 h,
40 rpm in a DPM 3Mixer (Charles Ross and Son Company, Hauppa-
uge, NY). Methylparaben (Spectrum Chemical, New Brunswick, NJ)
in PBS was added (0.2% ﬁnal concentration) and the solution stir-
red for 1 h at 40 rpm. The pH was adjusted to 6.5–7.0 with 1 N
HCl (Ricca Chemical, Pocomoke City, MD). Bubbles were removed
by stirring for 15 min under vacuum. Clean Chemical Sweden
(Borlänge, Sweden) manufactured hydroxyethylcellulose (HEC)
placebo gel, using the literature procedure (Tien et al., 2005).
Non-sulfated cellulose derivatives like HEC are inactive against
HPV (Buck et al., 2006). HEC gel is the universal microbicide
placebo, having substantial safety data (Richardson et al., 2013).
2.2. Gel properties and CG content
PC-515 and Divine 9 (Divine Corporation, Orlando, FL) were
tested for viscosity, rheology, pH, osmolality, turbidity, and CG
content. Viscosity was measured using a calibrated Brookﬁeld
(Middleboro, MA) DV-II + viscometer (SC4-28 spindle, 5 rpm,
SC4-13RPY chamber, 37 C). Rheology was characterized using a
calibrated AR 1500ex Rheometer (TA Instruments, New Castle,
DE) outﬁtted with 4, 40 mm diameter, and 108 lm truncation
geometry. Viscosity was measured over shear rates of 0.1–
120 s1. Gel pH was tested using an Orion 4 Star digital pH Meter
(ThermoFisher Scientiﬁc, Waltham, MA). Osmolality was measured
using a calibrated Vapro 5520 osmometer (Wescor, Logan, UT).
Formulations were considered iso-osmolal or nearly iso-osmolal
at 200–500 mOsmol/kg. Turbidity was measured using the absor-
bance (vs. standards) of a sample at 450 nm in an Emax plate
reader (Molecular Devices, Sunnyvale, CA). CG content was deter-
mined using methylene blue (Soedjak, 1994).
2.3. Cells and viruses
HeLa cells (ATCC, Rockville, MD) were grown in DMEM (Life
Technologies, Grand Island, NY) supplemented with 10% heat inac-
tivated fetal bovine serum (Life Technologies) and 50 U/ml of pen-
icillin and 50 lg/ml streptomycin (Life Technologies).
HPV-PsVs: HPV16, 18, and 45 PsVs were produced as previously
described (Kizima et al., 2014). HPV-PsV stocks were titered by
quantitative PCR (qPCR), in an ABI ViiA 7 thermal cycler (Kizima
et al., 2014).
2.4. Cytotoxicity and anti-HPV activity
Cytotoxicity and anti-HPV activity were tested in HeLa cells
(Kizima et al., 2014). Brieﬂy, HeLa cells were plated (104 cells/well)
in 100 ll of medium and incubated overnight at 37 C, 5% CO2, and
98% humidity (standard conditions). Test gels were diluted in med-
ium to obtain 2 dilutions of the appropriate dilution range. Cell
culture media on the cell monolayers was replaced with 50 ll of
the diluted formulations or 50–100 ll of medium for virus and cell
controls. Dilutions were tested in triplicate. Fifty ll of HPV 16, 18
or 45 PsVs (5  105 copies) were added to all wells with the excep-
tion of cell controls and incubated for 72 h at standard conditions.
Cells were lysed to detect luciferase activity using the Pierce Fireﬂy
Luciferase Glow Assay with Pierce Fireﬂy Signal Enhancer (Thermo
Scientiﬁc) as described by the manufacturer. Luminescence was
read on a Gemini EM microplate reader (emission 542 nm) using
Softmax Pro 3.2.1 software. Cytotoxicity was estimated using the
XTT assay (Fernández-Romero et al., 2007), mimicking the antiviralassay but without virus. CC50 and IC50 values were calculated using
a dose–response–inhibition analysis on GraphPad Prism v5.0c soft-
ware. Therapeutic indexes (TI = CC50/IC50) were calculated.
2.5. HPV-16 and 45 PsV mouse model
We followed the Animal Welfare Act (Code of Federal
Regulations, 2001) and the Guide for the Care and Use of laboratory
Animals (National Research Council, 2010). Rockefeller University’s
Institutional Animal Care and Use committee (IACUC) of the Com-
parative Bioscience Center (CBC) approved animal protocols. We
tested the in vivo anti-HPV activity of CG formulations using the
mouse HPV PsV model (Kizima et al., 2014; Roberts et al., 2007).
Ten ll of PC-515, Divine 9, or HEC were applied intravaginally at
24 h, 2 h, or 10 min before challenging with 8  106 copies/10 ll
of HPV16 PsV. Separately, we also applied PC-515 or HEC gel
2 h/+2 h virus challenge with HPV16 or HPV45 PsV in the pres-
ence or absence of 100% pooled human SP (Lee Biosolutions, St.
Louis, MO).
2.6. CG pharmacokinetics (PK) in mice and CG detection
PK studies were performed by instilling intravaginally 10 ll of
PC-515 or Divine 9 (n = 6 per gel). Vaginal washes (200 ll of
D-PBS) were collected after 1, 2, 4, 8 or 24 h. Native cervicovaginal
ﬂuid volume was not factored into the ﬁnal calculations. A CG
ELISA was used to quantify CG [Lower Limit of Quantiﬁca-
tion = 40 ng/ml] (Kizima et al., 2014).
2.7. Statistical analyses
ANOVA was used to analyze the log-transformed radiance
across treatments in the HPV PsV mouse model. The F test was
used for overall comparison between treatments and pairwise
comparisons were performed using Tukey–Kramer adjusted t tests.
Areas under the curve between 1 and 24 h (AUCs1–24) were com-
pared using a t test with pooled variance on the natural logarithm
of these AUCs.
3. Results
3.1. Carrageenan content and gel properties
PC-515 contains more CG than Divine 9: 30.6 mg/ml and
14.0 mg/ml, respectively, (Table 1). Divine 9 is less viscous than
PC-515 and hypo-osmolal; PC-515 is iso-osmolal. Both are shear-
thinning gels, becoming less viscous at shear stresses (Fig. 1)
experienced during sexual activity. PC-515 has the higher initial,
terminal, and overall maximum viscosities.
3.2. In vitro and in vivo efﬁcacy against HPV PsVs
PC-515 and Divine 9 were active in vitro against three predom-
inant HPV types (16, 18 and 45) (Fig. 2). Their IC50 values were
between 1/106 and 1/107 based on gel dilutions, which corre-
sponds to CG concentrations between 1 and 20 ng/ml. Neither
Fig. 1. Rheological proﬁles of PC-515 and Divine 9 demonstrate differences in
magnitude of viscosity, but similar shear thinning behavior. Rheological samples
were analyzed in a shear rate ﬂow from 0.1 to 120 s1, while monitoring viscosity.
The graph shows the log viscosity vs. log shear rate.
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Both showed highly selective (TI above 17,000) antiviral activity
(Fig. 2B).
In vivo efﬁcacy was determined by applying formulations 24 h
pre challenge or 2 h pre/2 h post to mimic the CAPRISA 004 dosing
regimen and that proposed for a Phase 2b clinical trial at Albert
Einstein College of Medicine (AECOM). Regardless of dosing regi-
men, PC-515 and Divine 9 signiﬁcantly decreased HPV16-PsV
infection compared to HEC placebo (p < 0.0001 vs. PC-515 or
Divine 9) (Fig. 3A and Table 2). PC-515 protected signiﬁcantly bet-
ter than Divine 9 when applied 24 h before PsV challenge
(p < 0.0001), protecting as effectively as Divine 9 applied 2 h pre/
2 h post PsV challenge (p = 0.9841) (Fig. 3A and Table 2).
In a separate experiment, CG was detected in mouse vaginal
washes 1, 2 and 4 h post-PC-515 application at concentrations
between 50 and 200 lg/ml, which dropped off at 24 h to between
20 and 80 lg/ml (Fig. 3B). CG concentrations were lower in the
Divine 9 washes taken at the same times; no CG was detected at
24 h. The CG AUC1–24 h in the mice receiving PC-515 is 9.3 times
higher than for mice receiving Divine 9 (p-value < 0.0001). CG con-
centrations after PC-515 dosing are 3000–10,000 times CG’s in vitro
IC50 (see Table 3).
Knowing that women could be exposed to HPV admixed with
SP and several sulfated/sulfonated polymers demonstrated
reduced antiviral activity in the presence of SP or in postcoital sam-
pling (Herold et al., 2011; Keller et al., 2010; Patel et al., 2007;Fig. 2. PC-515 and Divine 9 are non-toxic and have a potent and broad anti-HPV activity i
HPV-16, 18 and 45 IC50 values (shown as a vertical dotted line within the 95% conﬁdence
gel dilutions were tested in triplicate showing mean ± SD. Therapeutic Indexes (TI = CC5Segarra et al., 2011), we tested the antiviral activity of CG against
HPV-16 and HPV-45 PsV in the presence of SP. These main onco-
genic HPVs rendered high enough titers to use in the HPV PsV
mouse model. Fig. 4 shows that PC-515 retained potent anti-
HPV16 and 45 activities when applied 2 h pre/2 h post PsV
challenge in the presence or absence of 100% pooled human SP
compared to placebo-treated mice (p < 0.0001).4. Discussion
Complementary strategies to decrease HPV infections include
combining topical pre or post exposure microbicides and vaccines
for primary prevention with early detection and treatment of
infection by carcinogenic HPV types.
We previously reported the anti-HPV activity of an MZC gel
containing 3% CG (Kizima et al., 2014). Here we examine CG-only
formulations that are being considered for Phase 2b trials, looking
at their in vitro and in vivo efﬁcacy against HPV and the durability
of the activity. MZC gel’s anti-HPV activity is due entirely to its CG
content, so we do not expect any difference in the anti-HPV activity
of MZC gel and PC-515.
CG’s in vitro activity is independent of the CG type (lambda,
kappa, iota) and might be signiﬁcant when applied after virus chal-
lenge (Buck et al., 2006). CG is thought to inhibit HPV binding to
heparan sulfate on cell surface proteoglycans, but may also block
subsequent events that facilitate virion binding and entry into epi-
thelial basal cells (Buck et al., 2006). We report inhibition of PsVs
produced in 293T cells. These PsVs may have a different mode of
adsorption compare to HPVs produced in raft cultures (Cruz and
Meyers, 2013). However, CG’s ability to block post-adsorption
steps may afford similar inhibition using both virus sources.
CG’s anti-HPV IC50 ranges from 1 to 20 ng/ml; CG’s anti-HIV IC50
is approximately 3 lg/ml (Fernández-Romero et al., 2007). This
1000-fold difference could explain the lack of anti-HIV activity in
the Phase 3 Carraguard trial but the potential anti-HPV activity
in a subgroup of adherent women in the trial (Marais et al.,
2011). The weak anti-HIV activity and short duration of ﬁrst gener-
ation microbicides (mostly polyanions), plus low gel adherence,
may partially explain the results of the ﬁrst generation clinical
trials (Romano et al., 2012). Here we demonstrated a signiﬁcantn vitro. (A) Cytotoxicity was estimated using the XTT assay in HeLa cells. (B) The anti-
interval shaded in gray) were estimated using the luciferase assay in HeLa cells. All
0/IC50) are >17,000 for both formulations.
Fig. 3. PC-515 is signiﬁcantly more protective to mice against vaginal HPV-16 PsV infection than Divine 9. (A) Depo-treated Balb/C mice were given the indicated
formulations (HEC, PC-515, or Divine 9) intravaginally at 24 h before (24 h) or 2 h before and 2 h after (2 h/+2 h) HPV 16 PsV challenge (n = 15/treatment). In vivo luciferase
expression is expressed as mean luminescence in photons per second per centimeter square per steradian ± SD for each individual animal. The statistical analysis comparing
treatment groups is shown in Table 2. (B) CG levels (mean lg/ml ± SD) in vaginal washes from mice treated intravaginally with PC-515 or Divine 9 were determined at 1, 2, 4,
8 and 24 h post-gel (n = 6 per time point). There is signiﬁcant difference (p < 0.0001) between PC-515 AUC1–24 (geometric mean AUC1–24 hlg/ml = 1426.3) and Divine 9
AUC1–24 (geometric mean AUC1–24 h lg/ml = 153.8). CG concentrations were assumed to be log-normally distributed and a LLOQ of 40 ng/ml was taken into consideration.
Table 2
Statistical analysis comparing PC-515 vs. Divine 9 in the HPV mouse model.
Pairwise comparison Tukey–Kramer (p value)
Formulation 1 Treatment relative to HPV challenge Formulation 2 Treatment relative to HPV challenge
Divine 9 24 h HEC 2 h/+2 h <0.0001
PC-515 24 h HEC 2 h/+2 h <0.0001
Divine 9 2 h/+2 h HEC 2 h/+2 h <0.0001
PC-515 2 h/+2 h HEC 2 h/+2 h <0.0001
PC-515 24 h Divine 9 24 h <0.0001
Divine 9 2 h/+2 h Divine 9 24 h <0.0001
PC-515 2 h/+2 h Divine 9 24 h <0.0001
Divine 9 2 h/+2 h PC-515 24 h 0.9841
PC-515 2 h/+2 h PC-515 24 h 0.0338
PC-515 2 h/+2 h Divine 9 2 h/+2 h 0.1220
Table 3
In vivo PC-515 efﬁcacy in the presence or absence of SP.
Pairwise comparison Tukey–
Kramer
(p value)
Formulation 1 HPV inoculum
media
Formulation 2 HPV inoculum
media
HPV 16 PsV
HEC PBS HEC SP 0.1398
PC-515 PBS HEC PBS <0.0001
PC-515 SP HEC PBS <0.0001
PC-515 PBS HEC SP <0.0001
PC-515 SP HEC SP <0.0001
PC-515 SP PC-515 PBS 0.9704
HPV 45 PsV
HEC PBS HEC SP 0.0051
PC-515 PBS HEC PBS <0.0001
PC-515 SP HEC PBS <0.0001
PC-515 PBS HEC SP <0.0001
PC-515 SP HEC SP <0.0001
PC-515 SP PC-515 PBS 0.9996
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HPV PsV challenge.
The complete reduction of HPV PsV infection by PC-515 (2 h/
+2 h) is associated with CG levels of around 100 lg/ml in vaginal
washes; Divine 9 produces similar levels for only 1 h after single
gel application. Similar CG concentrations (median: 98 lg/ml,
range, <25–282 lg/ml) have been found in a Phase 1 safety trial
where cervicovaginal lavages (CVL) were collected 8–24 h after
vaginal application of a 3% CG gel (Haaland et al., 2012). Theseresults suggest that PC-515 will durably protect adherent
participants.
Our in vivo data show that CG’s anti-HPV activity is unaffected
by the presence of SP. SP was shown to inhibit the binding of
PRO 2000 and cellulose sulfate to HSV-2, resulting in decreased
protection of mice intravaginally challenged with HSV-2 (Patel
et al., 2007). Additionally, low postcoital bioavailability and antivi-
ral activity of PRO 2000 in CVLs support the experiments done in
mice (Keller et al., 2010). Cellulose sulfate showed decreased anti-
viral activity in the presence of SP and enhanced viral replication
probably by disrupting the epithelial barrier (Mesquita et al.,
2009). These results may explain why PRO 2000 and cellulose
sulfate failed to prevent HIV or HSV-2 in clinical trials.
PC-515 and Divine 9 have similar in vitro IC50 values when the
formulations are diluted equally. However, PC-515 protects better
against HPV PsV infection in vivo compared to Divine 9, which is
perhaps due to differences in their physicochemical and rheologi-
cal properties.
Here we show that formulations with similar in vitro efﬁcacy
but different rheological properties have signiﬁcantly different PK
proﬁles and in vivo anti-HPV activity. Shear thinning is a critical
gel property, ensuring that during sexual activity the gel will
spread uniformly throughout the vagina, protecting all surfaces
against viral infection. A computational model was used to deter-
mine the optimal rheology for intravaginal gel spreading
(Fernández-Romero et al., 2012), showing that PC-515 and other
thixotropic CG gels with viscosities between 24,000 and
40,000 cP cover the entire surface area of the human vagina
(100 cm2). Lower viscosity gels like Divine 9 may spread effec-
tively. However, they may leak or be washed away rapidly, result-
Fig. 4. Seminal plasma does not affect the in vivo anti-HPV activity of PC-515. Depo-treated Balb/C mice were given the indicated formulations (HEC or PC-515) under the
2 h/+2 h regimen relative to challenge with either HPV 16 or HPV 45 PsV challenge in SP or PBS (n = 15/group). In vivo luciferase is expressed as mean luminescence in
photons per second per centimeter squared per steradian ± SD for each individual animal. The statistical analysis comparing treatment groups is shown in Table 3.
92 A. Rodríguez et al. / Antiviral Research 108 (2014) 88–93ing in sub-effective concentrations of gel in the vaginal lumen,
shorter durability, and poor acceptability.
Divine 9 is hypo-osmolal; PC-515 is nearly iso-osmolal. Hyper-
osmolal or hypo-osmolal vaginal or rectal formulations may dam-
age epithelial tissue, leading to increased susceptibility to STIs. We
and others have investigated the effect of osmolality of sexual
lubricants on the integrity of the epithelium, ﬁnding that a number
of hyper-osmolal commercial lubricants are associated with cellu-
lar toxicity and epithelial damage (Begay et al., 2011; Dezzutti
et al., 2012; Fuchs et al., 2007). Moreover, a recent publication
suggests that some lubricants may increase vulnerability to STIs
(Gorbach et al., 2012). Although concerns have been raised primar-
ily around hyper-osmolal formulations, the safety of a hypo-
osmolal formulation like Divine 9 should be investigated and
addressed, if needed.
CG was the main ingredient in Carraguard, an experimental
microbicide gel that the Council tested in a Phase 3 clinical trial
(Skoler-Karpoff et al., 2008). CG gel does not damage vaginal or rec-
tal epithelial tissue in mice. It does not increase susceptibility to
HSV-2 vaginal infection in mice and is nontoxic to Lactobacillus
jensenii or Lactobacillus crispatus in vitro (Kenney et al., 2013).
Experiments in macaques show that repeated application is safe
with no effects on vaginal pH or cytokines and chemokine levels
in ﬂuids (Kenney et al., 2011). Finally Phase 1, 2 and 3 clinical trials
have demonstrated that vaginal application of a 3% CG gel is safe
and acceptable (Kilmarx et al., 2008, 2006; Martin et al., 2010;
Skoler-Karpoff et al., 2008; Whitehead et al., 2006).
Considering the excellent safety proﬁle, rheological properties,
and anti-HPV activity of a 3% CG gel, we have used CG-based gels
as delivery vehicles for anti-HIV and anti-HSV-2 APIs (Fernández-
Romero et al., 2012; Kenney et al., 2011, 2013, 2012; Kizima
et al., 2014).
A strategy combining microbicides like PC-515 and MZC with
vaccination and early diagnosis could effectively prevent HPV
acquisition. CG signiﬁcantly prevents in vitro and in vivo infection
by different HPV genotypes (Buck et al., 2006), overcoming one
of the limitations of the current vaccines. However, the recent
VOICE Trial results showed that microbicide gels face signiﬁcant
adherence challenges (Van Damme et al., 2012; van der Straten
et al., 2012), some of which are related to fear of partner’s detec-
tion of gel use and uncooperative partners (Muchomba et al.,
2012). Adherence issues may also be linked to daily-use products,
since potential users may not acknowledge their HPV, HSV-2, or
HIV risk daily. These issues prompted the Council and others to
develop delivery systems like intravaginal rings and nanoﬁbers
to increase adherence.
Our results conﬁrm the durable, broad-spectrum in vivo activity
of a CGgel againstHPV, even in the presence of SP. These results sup-
port further testing of CG formulations to prevent HPV acquisition.Conﬂict of interest
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